 CytoDyn Inc OTCQB:CYDY, which is developing Vyrologix leronlimab-PRO 140 for multiple indications, has said that its Brazilian distribution partner Biomm SA BVMF:BIOM3 plans to submit an authorization request to the Brazilian National Health Surveillance Agency ANVISA, to conduct two Phase 3 clinical trials of leronlimab in Brazil for coronavirus COVID-19 patients. The Vancouver, Washington-based late-stage biotech said the request will be submitted to ANVISA in the next few days to conduct two Phase 3 trials for a batch of critically ill COVID-19 patients, and another severely ill population. 